Format

Send to

Choose Destination
J Hepatol. 2016 Jun;64(6):1403-15. doi: 10.1016/j.jhep.2016.02.004. Epub 2016 Feb 8.

IL-6 pathway in the liver: From physiopathology to therapy.

Author information

1
Institute of Biochemistry, Christian-Albrechts-University Kiel, Olshausenstrasse 40, Kiel, Germany.
2
Institute of Biochemistry, Christian-Albrechts-University Kiel, Olshausenstrasse 40, Kiel, Germany. Electronic address: rosejohn@biochem.uni-kiel.de.

Abstract

Interleukin 6 (IL-6) is a pleiotropic four-helix-bundle cytokine that exerts multiple functions in the body. In the liver, IL-6 is an important inducer of the acute phase response and infection defense. IL-6 is furthermore crucial for hepatocyte homeostasis and is a potent hepatocyte mitogen. It is not only implicated in liver regeneration, but also in metabolic function of the liver. However, persistent activation of the IL-6 signaling pathway is detrimental to the liver and might ultimately result in the development of liver tumors. On target cells IL-6 can bind to the signal transducing subunit gp130 either in complex with the membrane-bound or with the soluble IL-6 receptor to induce intracellular signaling. In this review we describe how these different pathways are involved in the physiology and pathophyiology of the liver. We furthermore discuss how IL-6 pathways can be selectively inhibited and therapeutically exploited for the treatment of liver pathologies.

KEYWORDS:

Cancer; Inflammation; Interleukin-6; Interleukin-6-receptor; Liver regeneration; Trans-signaling

PMID:
26867490
DOI:
10.1016/j.jhep.2016.02.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center